RxDoctor Payments DataLook up a doctor →

Marc Bernstein, MD

Cardiovascular Disease · Slidell, LANPI 1851333587

Payments from drug & device makers

$2,140,211in general payments, 2019–2025

Across 1,553 payments — averaging $1378.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$657K
  • Novartis$492K
  • Novo Nordisk AS$410K
  • Janssen Research & Development, LLC$191K
  • Eli Lilly$146K
  • Boehringer Ingelheim International GmbH$80K
  • plus $164K from 54 others
$45,424in research payments, 2019–2025

Across 1 payment — averaging $45,424 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$45K

What the payments were for

  • Speaking & faculty fees$1,2007%
  • Food & beverage$14,62991%
  • Education$2542%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen103$657,466
Novartis206$492,299
Novo Nordisk AS410$409,584
Janssen Research & Development, LLC34$191,042
Eli Lilly4$146,448
Boehringer Ingelheim International GmbH88$79,522
Merck56$44,212
AstraZeneca44$41,612
Boehringer Ingelheim Pharma GmbH & Co.kg6$36,424
Pfizer123$30,884
Johnson & Johnson83$1,218
Acarix USA Inc.1$1,200
E.r. Squibb & Sons, L.L.C.61$1,017
Medtronic(2 entities)59$972
Boehringer Ingelheim32$887
Philips North America LLC10$712
Esperion Therapeutics, Inc.27$410
Sanofi-aventis U.S. LLC24$398
Bayer24$383
Novo Nordisk19$373
Lilly USA, LLC18$371
Amarin Pharma, Inc.15$253
Astellas Pharma US Inc3$179
Impulse Dynamics (USA) Inc.3$170
Boston Scientific7$157
Regeneron Healthcare Solutions, Inc.8$149
Biotronik Inc.1$130
Kowa Pharmaceuticals America, Inc.9$126
Actelion Pharmaceuticals US, Inc.6$125
Arbor Pharmaceuticals, Inc.9$121
Abbott2$113
Valeritas, Inc.1$110
Scpharmaceuticals Inc.6$105
GSK6$96
Itamar Medical Inc2$95
Covidien LP1$87
Lexicon Pharmaceuticals, Inc.4$81
Tactile Systems Technology Inc4$67
Lundbeck LLC4$63
United Therapeutics Corporation3$60
Irhythm Technologies, Inc.3$60
Cvrx, Inc.2$42
Otsuka America Pharmaceutical, Inc.2$40
Sanofi Pasteur Inc.2$30
Dexcom, Inc.1$29
Cook Medical LLC1$29
Amryt Pharma Holdings Ltd2$28
Nuwellis, Inc.1$28
Celonova Biosciences, Inc.1$23
Kiniksa Pharmaceuticals, Ltd.1$23
Gilead2$22
Medicomp Inc1$21
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$20
Azurity Pharmaceuticals, Inc.1$19
Silk Road Medical, Inc.1$18
Cardiva Medical, Inc.1$16
Baxter Healthcare1$14
Cardiovascular Systems Inc.1$13
Convatec Inc.1$12
Bardy Diagnostics, Inc.1$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,140,211 in reported general payments places this provider in the 95th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$459,915
Medicare patients
658
Services billed
7,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban773$731,255
MounjaroTirzepatide309$395,073
EntrestoSacubitril/Valsartan350$339,688
OzempicSemaglutide190$240,093
Repatha SureclickEvolocumab306$220,286
XareltoRivaroxaban251$219,100
JardianceEmpagliflozin132$141,413
FarxigaDapagliflozin Propanediol125$106,954
VascepaIcosapent Ethyl109$60,644
NexlizetBempedoic Acid/Ezetimibe113$56,377
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$34,925
BrilintaTicagrelor56$31,964
MultaqDronedarone Hcl30$25,779
WegovySemaglutide16$23,176
TrulicityDulaglutide13$22,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30,884$731,255773 claims
Lilly USA, LLCMounjaro, Trulicity$371$417,248322 claims
NovartisEntresto$492,299$339,688350 claims
Novo NordiskOzempic, Wegovy$373$263,269206 claims
Johnson & JohnsonXarelto$1,218$219,100251 claims
Boehringer IngelheimJardiance$887$141,413132 claims
AstraZenecaFarxiga, Brilinta$41,612$138,918181 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$410$72,102142 claims
GSKTrelegy Ellipta, Breo Ellipta$96$44,52151 claims
Sanofi-aventis U.S. LLCMultaq$398$25,77930 claims
AmgenCorlanor$657,466$13,67124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →